Safety of factor VIII inhibitor bypass activity (FEIBA® ): 10-year compilation of thrombotic adverse events
Author:
Publisher
Wiley
Subject
Genetics(clinical),Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2516.2002.00532.x/fullpdf
Reference36 articles.
1. Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A;Ehrlich;Thromb Haemost,1998
2. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates;Kreuz;Vox Sang,1999
3. Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T;Penner;Haemophilia,1999
4. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors;Hilgartner;Blood,1983
5. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients;Hilgartner;Transfusion,1990
Cited by 206 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Safety and efficacy of fixed versus variable-dose prothrombin complex concentrate for emergent reversal of vitamin K antagonists: A systematic review and meta-analysis;The American Journal of Emergency Medicine;2024-03
2. Comparative study of predisposition to thrombosis with administration of known systemic hemostatic agents and fibrin monomer in the experiment;Bulletin of Siberian Medicine;2023-01-19
3. Massive Clot Formation Following FEIBA and Tranexamic Acid Administration in Postcardiopulmonary Bypass Hemorrhage;Journal of Cardiothoracic and Vascular Anesthesia;2022-10
4. Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study;European Journal of Haematology;2022-09-12
5. A Historical Perspective on the Reversal of Anticoagulants;Seminars in Thrombosis and Hemostasis;2022-09-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3